Antibiotics have a role in the management of acute exacerbations of bronchiectasis and may also benefit selected subsets of patients with bronchiectasis as a part of a long-term maintenance strategy. At present, there are no Food and Drug Administration-approved antibiotics for acute or chronic management of bronchiectasis. Clinical trials are underway to determine the efficacy and safety of various inhaled antibiotics for chronic therapy for bronchiectasis. Until those results are available, clinicians need to tailor their therapies to individual patients based on their best clinical judgment and information from data and guidelines currently available in the published literature.